{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:00:53Z","timestamp":1791986453320,"version":"4.4.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1A6A3A01087141"],"award-info":[{"award-number":["2022R1A6A3A01087141"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2023R1A2C1002940"],"award-info":[{"award-number":["2023R1A2C1002940"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.canlet.2024.217339","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T23:21:12Z","timestamp":1732663272000},"page":"217339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications"],"prefix":"10.1016","volume":"610","author":[{"given":"Mi-So","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4664-4162","authenticated-orcid":false,"given":"Seung-Woo","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi-Eun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Yeon","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0379-2790","authenticated-orcid":false,"given":"Tae-Nam","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Kil","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Hyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Seog","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Sun","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6371-7971","authenticated-orcid":false,"given":"Sun-Hee","family":"Leem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.217339_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca-Cancer J Clin"},{"key":"10.1016\/j.canlet.2024.217339_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.217339_bib3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"van Rhijn","year":"2009","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2024.217339_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2024.217339_bib5","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1001\/jama.2018.4656","article-title":"Simplifying treatment and reducing recurrence for patients with early-stage bladder cancer","volume":"319","author":"Kaffenberger","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2024.217339_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/UPJ.0000000000000481","article-title":"US clinical practice patterns of intravesical chemotherapy for Bacillus calmette-guerin-unresponsive and Bacillus calmette-guerin-exposed nonmuscle-invasive bladder cancer","volume":"11","author":"Abou Chakra","year":"2024","journal-title":"Urol Pract"},{"key":"10.1016\/j.canlet.2024.217339_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euros.2024.01.013","article-title":"The safety, tolerability, and preliminary efficacy of a gemcitabine-releasing intravesical system (TAR-200) in American urological association-defined intermediate-risk non-muscle-invasive bladder cancer patients: a phase 1b study","volume":"62","author":"Fj","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.canlet.2024.217339_bib8","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/JU.0000000000003195","article-title":"Safety, tolerability, and preliminary efficacy of TAR-200 in patients with muscle-invasive bladder cancer who refused or were unfit for curative-intent therapy: a phase 1 study","volume":"209","author":"Tyson","year":"2023","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2024.217339_bib9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/bju.16208","article-title":"Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer","volume":"133","author":"McElree","year":"2024","journal-title":"BJU Int."},{"key":"10.1016\/j.canlet.2024.217339_bib10","first-page":"33","article-title":"Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC","volume":"18","author":"Garneau","year":"2024","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.canlet.2024.217339_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs Bacillus calmette-guerin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.canlet.2024.217339_bib12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2023.06.011","article-title":"Sequential intravesical gemcitabine and docetaxel is an alternative to Bacillus calmette-guerin for the treatment of intermediate-risk non-muscle-invasive bladder cancer","volume":"6","author":"Tan","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.canlet.2024.217339_bib13","doi-asserted-by":"crossref","first-page":"458e451","DOI":"10.1016\/j.urolonc.2023.06.018","article-title":"Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy","volume":"41","author":"Yim","year":"2023","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.canlet.2024.217339_bib14","doi-asserted-by":"crossref","first-page":"148e141","DOI":"10.1016\/j.urolonc.2022.10.030","article-title":"Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer","volume":"41","author":"Chevuru","year":"2023","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.canlet.2024.217339_bib15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/JU.0000000000002848","article-title":"Sequential intravesical valrubicin and docetaxel for the salvage treatment of non-muscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2024.217339_bib16","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.euf.2023.06.006","article-title":"Background and update for ECOG-ACRIN EA8212: a randomized phase 3 trial of intravesical Bacillus calmette-guerin (BCG) versus intravesical docetaxel and gemcitabine treatment in BCG-naive high-grade non-muscle-invasive bladder cancer (bridge)","volume":"9","author":"Kates","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.canlet.2024.217339_bib17","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2024.217339_bib18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.urolonc.2020.10.009","article-title":"At a time of global BCG shortage, attempts at optimizing BCG dose and schedule is no longer the answer","volume":"39","author":"Morales","year":"2021","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.canlet.2024.217339_bib19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semcancer.2019.08.019","article-title":"Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion","volume":"60","author":"D'Alterio","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2024.217339_bib20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.trecan.2019.02.003","article-title":"Polytherapy and targeted cancer drug resistance","volume":"5","author":"Chatterjee","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2024.217339_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","article-title":"Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes","volume":"17","author":"Meeks","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.canlet.2024.217339_bib22","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/sj.bjc.6605912","article-title":"How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine","volume":"103","author":"Gerlinger","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2024.217339_bib23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41420-022-01242-8","article-title":"Stepwise molecular mechanisms responsible for chemoresistance in bladder cancer cells","volume":"8","author":"Mun","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2024.217339_bib24","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s43440-020-00138-7","article-title":"Drug resistance in cancer: mechanisms and tackling strategies","volume":"72","author":"Haider","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.canlet.2024.217339_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.critrevonc.2015.05.005","article-title":"Emerging concepts on drug resistance in bladder cancer: implications for future strategies","volume":"96","author":"Massari","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2024.217339_bib26","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.217339_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.canlet.2014.03.013","article-title":"Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches","volume":"347","author":"Wu","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217339_bib28","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.7150\/thno.21713","article-title":"miR34a\/GOLPH3 Axis abrogates urothelial bladder cancer chemoresistance via reduced cancer stemness","volume":"7","author":"Zhang","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2024.217339_bib29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/BLC-180167","article-title":"Systematic review: characteristics and preclinical uses of bladder cancer cell lines","volume":"4","author":"Zuiverloon","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.canlet.2024.217339_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.neo.7900231","article-title":"MIM, a potential metastasis suppressor gene in bladder cancer","volume":"4","author":"Lee","year":"2002","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2024.217339_bib31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1039\/C9LC00958B","article-title":"Exosome-mediated microRNA-497 delivery for anti-cancer therapy in a microfluidic 3D lung cancer model","volume":"20","author":"Jeong","year":"2020","journal-title":"Lab Chip"},{"key":"10.1016\/j.canlet.2024.217339_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.canlet.2024.217339_bib33","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.canlet.2024.217339_bib34","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.217339_bib35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s13059-019-1874-1","article-title":"Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression","volume":"20","author":"Hafemeister","year":"2019","journal-title":"Genome Biol."},{"key":"10.1016\/j.canlet.2024.217339_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.217339_bib37","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.217339_bib38","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.217339_bib39","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2009.25.0977","article-title":"Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors","volume":"28","author":"Lee","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.217339_bib40","article-title":"Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight","volume":"2","author":"Hurst","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.canlet.2024.217339_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn4118","article-title":"Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guerin","volume":"15","author":"de Jong","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2024.217339_bib42","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1038\/s41467-020-18916-5","article-title":"Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma","volume":"11","author":"Chen","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.217339_bib43","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2024.217339_bib44","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00204-021-03063-7","article-title":"Cancer drug resistance induced by EMT: novel therapeutic strategies","volume":"95","author":"De Las Rivas","year":"2021","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.canlet.2024.217339_bib45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.critrevonc.2019.02.010","article-title":"Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer","volume":"137","author":"Gonzalez-Avila","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2024.217339_bib46","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/0008-5472.CAN-10-0730","article-title":"Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer","volume":"71","author":"Thomas","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217339_bib47","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/ijc.29658","article-title":"L1CAM in human cancer","volume":"138","author":"Altevogt","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2024.217339_bib48","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217339_bib49","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.217339_bib50","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.217339_bib51","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2024.217339_bib52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2024.217339_bib53","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2024.217339_bib54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cell.2011.05.040","article-title":"Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis","volume":"146","author":"Goetz","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.217339_bib55","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s12276-020-0447-4","article-title":"Targeting focal adhesion kinase in cancer cells and the tumor microenvironment","volume":"52","author":"Murphy","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2024.217339_bib56","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41419-021-03522-0","article-title":"Calcium channel alpha2delta1 subunit is a functional marker and therapeutic target for tumor-initiating cells in non-small cell lung cancer","volume":"12","author":"Ma","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2024.217339_bib57","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2024.217339_bib58","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.canlet.2020.11.046","article-title":"Forkhead box D1 promotes EMT and chemoresistance by upregulating lncRNA CYTOR in oral squamous cell carcinoma","volume":"503","author":"Chen","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217339_bib59","article-title":"Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment","volume":"2018","author":"Phi","year":"2018","journal-title":"Stem Cell. Int."},{"key":"10.1016\/j.canlet.2024.217339_bib60","article-title":"Targeting endothelial cell-specific molecule 1 protein in cancer: a promising therapeutic approach","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.217339_bib61","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3389\/fcell.2020.00766","article-title":"Tumor endothelial cells (TECs) as potential immune directors of the tumor microenvironment - new findings and future perspectives","volume":"8","author":"Nagl","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2024.217339_bib62","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.gendis.2015.07.003","article-title":"Promising molecular mechanisms responsible for gemcitabine resistance in cancer","volume":"2","author":"Jia","year":"2015","journal-title":"Genes Dis"},{"key":"10.1016\/j.canlet.2024.217339_bib63","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-019-0770-1","article-title":"Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.217339_bib64","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2024.217339_bib65","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0242","article-title":"nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer","volume":"2","author":"Frese","year":"2012","journal-title":"Cancer Discov."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524007341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524007341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:34:27Z","timestamp":1733499267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524007341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":65,"alternative-id":["S0304383524007341"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217339","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217339"}}